IMW 2021 | Ocular adverse events with ADCs

Katja Weisel • 10 Sep 2021

IMW 2021

Katja Weisel, MD, of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the incidence of ocular toxicity such as keratopathy and blurred vision associated with the use of antibody-drug conjugates (ADCs). Dr Weisel explains that this toxicity appears to be reversible with the use of prescribed eye drops at the initiation of treatment and by prolonging the interval between treatment. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

Disclosures

Katja Weisel, MD, has received institutional grant support from Amgen, BMS/Celgene, GSK and Sanofi; and has received honoraria from AbbVie, Amgen, Adaptive Biotech, BMS/Celgene, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche Pharma, Takeda and Sanofi.